AACE 2026 Resource Hub –
Welcome to our resource hub for AACE 2026! This is a one-stop-shop for all your AACE 2026 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.
Table of Contents []
Day-of Conference Reports
Diabetes Highlights
- Opening session places nutrition at the center of AACE 2026 Annual Meeting
- Role of AI in diabetes care: Leveraging CGM-driven insights to support agentic recommendations
- Global perspectives from Pakistan, Mexico, and India highlight diabetes heterogeneity and the need for context-specific care across regions
- Interdisciplinary strategies to detect and treat “at‑risk MASH”
- CKM discussion continues: Dr. Rodolfo Galindo emphasizes metabolic complexity and the need for standardized interpretation
- Dexcom product theater showcases CGM portfolio, evidence in non-insulin T2D, and Smart Basal titration platform
- Diabetes Year in Review: Treatment algorithm improvements for better care across T1D and T2D
- Dr. Michelle Look on exercise and nutrition recommendations during GLP-1 RA/GIP therapy for obesity
- Cardiometabolic “Year in Review”: Evolving lipid therapy guidelines and cardiometabolic strategies for long‑term risk reduction
- AACE’s prediabetes algorithm: Case studies to demonstrate efficacy
- Nutrition & Obesity Year in Review: Obesity care moves beyond BMI as pharmacologic options accelerate and nutrition remains foundational
- “Betting on basal”: Casino-themed night focused on how to improve odds for PWDs
- AACE 2026 algorithm update for adults with T2D: Expanding from glycemic management to a fully integrated cardiometabolic, complications-driven framework
- Dr. Viral Shah on the use of GLP-1 RAs for obesity and cardiometabolic management in T1D
- To BMI or not to BMI: An outdated metric or an important assessment tool in the management of obesity?
- Weekly basal insulin debate: Adherence and simplicity in T2D weighed against hypoglycemia risk and physiologic mismatch in T1D
- CGM in gestational diabetes: Debate highlights clear benefits in high-risk patients, but mixed evidence limits broad adoption
- AID enters the T2D guidelines as clinical trial and real-world data show rapid gains in TIR
- Addressing cardiovascular risk in T1D: Statins, non-statins, and beyond
- Dr. Linda DiMeglio on transforming early stage T1D through screening and disease modifying therapies
- Disrupting the status quo of underdiagnosis in hypercortisolism cases
- CGM and AID in the perioperative setting: Growing guideline support contrasts with variable real-world adoption
- Cell therapies in T1D move closer to clinic, as Breakthrough T1D CEO Dr. Aaron Kowalski outlines path to scalable cures
- Microdosing GLP 1 RAs as a practical strategy amid access barriers
- Obesity as a multisystem disease: Why liver assessment is essential in metabolic care
- Lilly's Foundayo shows meaningful weight loss and positions oral GLP-1 RAs for earlier obesity intervention
- Liver health: The new frontier in cardiometabolic management
- Madrigal product theater: The role of liver-directed therapy in MASLD/MASH
- Pediatric obesity management: Pharmacotherapy, surgery, and breaking down barriers